Photo taken from Matt Campbell/X
Apr 13, 2024, 09:52
Matt Campbell: The results of *two* Phase 2 studies of cabozantinib in Adrenal Cancer in The Lancet Oncology
Matt Campbell, Genitorurinary medical oncologist at UT MD Anderson Cancer center, shared a post on X:
“HOT OFF THE PRESS: Happy to share the results of *two* Phase 2 studies of cabozantinib in Adrenal Cancer in The Lancet Oncology from MD Anderson Cancer center.”
Source: Matt Campbell/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18